Effects of Raloxifene and GnRH-a on VEGF expression in cultured human uterine leiomyoma cells

Taravat Fakheri, Kamran Mansouri, Sahar Rashidi, Mansour Rezaei, Sara Daeichin, Anisodowleh Nankali


Background: uterine leiomyoma is the most common benign pelvic tumor in women of reproductive age and is frequently associated with abnormal uterine bleeding and pelvic pressure. Combined therapy of gonadotropin-releasing hormone analogue (GnRH-a) and selective estrogen receptor inhibitors (raloxifene) reduce the  size of leiomyoma.

Methods: Twelve uterine leiomyomas were obtained from pre-menopausal women with regular menstrual cycles in the proliferative phase who underwent abdominal hysterectomy or myomectomy in Imam Reza Hospital. The patients had received no hormonal therapy for at least 6 months before surgery.The comparative effects of treatment with graded concentrations of raloxifene (in five groups with various concentrations of 1, 2, 4, 6 and 8 micrograms per milliliter, respectively) and GnRH-a (in five groups, with concentrations of 50, 100, 200, 300 and 400 micrograms per milliliter, respectively) and combination of these two on Vascular Endothelial Growth Factor (VEGF) and inhibition of leiomyoma cell proliferation were determined.

Results: in the three treatment groups with graded concentration of raloxifene and GnRH-a and combined therapy, VEGF content significantly decreased (P<0.05). The VEGF decreasing levels in the combined therapy, raloxifene and GnRH-a groups were 79.16%, 64.74% and 55.29%, respectively (p<0.05). The inhibition of cell growth was significantly different between the two treatment groups (P<0.05). The inhibition of cell growth in the combined therapy group was 70.77% followed by raloxifene (60.76%) and GnRH-a (15.83%), which indicated a significant difference (P<0.05).

Conclusion: Treatment with graded concentrations of Raloxifene, GnRH-a and combination of both Raloxifene and GnRH-a significantly decreased the VEGF content and proliferation of leiomyoma cells.


Leiomyoma, raloxifene,VEGF,GnRH-a


Islam MS, Protic O, Giannubilo SR, Toti P, Tranquilli AL, Petraglia F, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013 Mar;98(3):921-34.

De Leo V, Morgante G. Uterine fibromas and the hormonal pattern: the therapeutic considerations. Minerva Ginecol. 1996;48(12):533-8.

Vollenhoven BJ, Herington AC, Healy DL. Epidermal growth factor and transforming growth factor-beta in uterine fibroids and myometrium. Gynecol Obstet Invest. 1995;40(2):120-4.

Van der Ven LT, Roholl PJ, Gloudemans T, Van Buul-Offers SC, Welters MJ, Bladergroen BA, et al. Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br J Cancer. 1997;75(11):1631-40.

Vu K, Greenspan DL, Wu TC, Zacur HA, Kurman RJ. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol. 1998;29(4):359-63.

Baytur YB, Ozbilgin K, Cilaker S, Lacin S, Kurtul O, Oruc S, et al. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2007;135(1):94-103.

Ohara N. Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma. Clin Exp Obstet Gynecol. 2005;32(1):9-11.

Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab. 1998;83(6):2192-8.

Toth-Jakatics R, Jimi S, Takebayashi S, Kawamoto N. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol. 2000;31(8):955-60.

Hermon TL, Moore AB, Yu L, Kissling GE, Castora FJ, Dixon D. Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. Virchows Arch. 2008;453(6):557-69.

Bartlett SR, Sawdy R, Mann GE. Induction of cyclooxygenase-2 expression in human myometrial smooth muscle cells by interleukin-1beta: involvement of p38 mitogen-activated protein kinase. J Physiol. 1999;520 Pt 2:399-406.

Gentry CC, Okolo SO, Fong LF, Crow JC, Maclean AB, Perrett CW. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond). 2001;101(6):691-5.

Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol. 1995;129(4):895-8.

Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab. 1995;80(6):1853-8.

Di Lieto A, De Falco M, Mansueto G, De Rosa G, Pollio F, Staibano S. Preoperative administration of GnRH-aplus tibolone to premenopausal women with uterine fibroids: evaluation of the clinical response , the Immunohistochemical expression of PDGf , bfGf and VEGf and the vascular pattern. steroids. 2005; 70 (2): 94-102.

Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig. 2005;12(2):123-8.

Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod. 2010;25(3):642-53.

Liu J, Matsuo H, Xu Q, Chen W, Wang J, Maruo T. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro. Hum Reprod. 2007;22(5):1253-9.

Wu T, Chen X , Xie L. Selective estrogen receptor modulators (SERMS) for uterine leiomyomas. copyright. Cochrane Database Syst Rev. 2007;(4):CD005287.

Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil Steril. 2001;76(1):38-43.

Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R. Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril. 2004;81(1):132-6.

Palomba S, Russo T, Orio FJr, Tauchmanova L, Zupi E, Panici PL, et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod. 2002;17(12):3213-9.

DOI: http://dx.doi.org/10.22110/jkums.v18i2.1552


  • There are currently no refbacks.

Copyright (c)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.